Efficacy of Getong Tongluo Capsule plus Clopidogrel hydrogen sulfate tablets Therapy Assisted by Home Rehabilitation Guidance in Convalescents from Cerebral Infarction.

Article

作者: Lin, Kuiming ; Lin, Xia

BackgroundCerebral infarction (CI) is one of the leading causes of death in middle-aged and elderly people, and there is a need to focus on overall rehabilitation during the recovery period of CI in the clinic, to provide a more reliable guarantee for the health of patients.ObjectiveTo observe the therapeutic efficacy of Getong Tongluo Capsule (GTC) plus Clopidogrel hydrogen sulfate tablets (CHST) therapy assisted by home rehabilitation guidance in convalescents from CI, to provide clinical reference and evidence for future CI management.MethodsCI convalescents who visited the Fourth People's Hospital of Haikou City between 2016 and 2021 were selected as the research participants. Based on the assistance of home rehabilitation guidance, 44 patients receiving CHST treatment and 56 patients receiving GTC + CHST treatment were assigned to a control group (CG) and research group (RG), respectively. The blood viscosity of the two groups was compared before and after treatment. In addition, patients were assessed by the National Institutes of Health Stroke Scale (NIHSS), Mini-Mental State Examination (MMSE), Fugl-Meyer Assessment (FMA), Modified Barthel index (MBI), and Self-rating Anxiety/Depression Scale (SAS/SDS) scores. Finally, the adverse reaction rate was counted.ResultsThe post-treatment blood viscosity decreased in both cohorts and was lower in RG compared with CG (P < .001). Regarding various scale scores, NIHSS, SAS, and SDS were lower in RG than CG, while MMSE, FMA, and MBI were higher (P < .001). The adverse reaction rate was not significantly different between groups (P = .587).ConclusionGTC + CHST therapy assisted by home rehabilitation guidance is effective in the treatment of CI patients in the convalescent stage and is worth recommending.

2009-07-01·Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine

[Clinical observation on treatment of 10 patients with chronic inflammatory demyelinating polyneuropathy by gullong tongluo capsule combined with prednisone].

Article

作者: Zhang, Zhi-Hui ; Chen, Jin-Liang ; Hu, Jun-Yong

OBJECTIVETo observe and evaluate objectively the clinical effect of Guilong Tongluo Capsule (GTC) in treating chronic inflammatory demyelinating polyneuropathy (CIDP).METHODSSixty CIDP patients were equally randomized into two groups. The treated group was administered with GTC and prednisone, while the control group with prednisone alone. Changes before and after 3-month treatment in terms of muscle force, functional and sensory disturbance of extremities, as well as scoring by Activity of Daily Living Scale (ADL) and electromyogram (EMG) for nerve conduction velocity were observed and compared.RESULTSThe total effective rate gained in the treated group and the control group was 90.0% (27/30) and 70.0% (21/30) respectively, showing significant difference between them (chi2 = 14.82, P < 0.01). The improvement in the treated group was superior to the control group in muscle force of lower limb, motive and sensory function of extremities, ADL scores and motive function of ulnar nerve (P < 0.05, P < 0.01).CONCLUSIONThe curative effect of GTC combined with prednisone in treating CIDP was better than that of prednisone alone.

项与天龙通络胶囊相关的新闻（医药）

2023-02-10

·PRNewswire

Tianlong New Product Panall 8000 Shines at Medlab Middle East 2023

XI'AN, China, Feb. 10, 2023 /PRNewswire/ -- Medlab Middle East 2023, a leading exhibition of laboratory medicine in ME region, was unveiled at Dubai World Trade Center from 6 to 9 February. As Tianlong's first show of 2023, we are well prepared and thrilled to welcome guests from all over the world and discuss the latest innovations in the IVD industry. Continue Reading Tianlong at Medlab Tianlong Panall 8000 debuted Tianlong introduces to the audience our innovative PCR lab solution, covering nucleic acid extractors, real-time PCR systems, sample processing systems, liquid handling systems, and compatible reagents. The star products from Tianlong have got recognition from new and old partners for its excellent performance and stable quality. This time, we have also launched our new product Panall 8000 All-in-one Molecular Diagnosis System and put it on the international stage. The new product has drawn the attention of a large number of customers to stop and watch. The new lab booster, Tianlong Panall 8000 is a simple and secure molecular diagnosis system that integrates the functions of sample tube decapping/capping, sample loading, nucleic acid extraction, PCR setup, PCR detection, and result analysis, which can realize a true sample in -result out detection process and bring great convenience for professionals with only one-key operation. Benefits: Sample in -result out system One key operation and walkaway workflow Closed system minimizes contamination 8 samples can be tested at the same time It's a great gathering in Dubai. Thanks to all our friends, partners, and colleagues for making Medlab Middle East 2023 a great success. Tianlong will always excel to make excellent products, and thanks for choosing Tianlong. We'll keep you informed of our latest shows and hope to have more interactions with you next time. About Tianlong Tianlong is an innovative high-tech company specializing in molecular diagnostic products in China. Since its foundation in 1997, Tianlong has devoted itself to providing integrated PCR lab solutions for professionals worldwide. We have a wide range of products covering from devices to reagents, including nucleic acid extractors, Real-time PCR systems, All-in-one molecular diagnosis systems, sample processing systems, liquid handling systems, and 300 kinds of compatible reagents. With NMPA, CE, and FDA marks, our products have been exported to more than 100 countries and regions worldwide and have greatly helped the prevention and control of epidemics such as COVID-19, SARS, avian influenza, Ebola, Zika, and African swine fever. SOURCE Xi'an TianLong Science and Technology Co., Ltd

诊断试剂

2022-11-15

·PRNewswire

Tianlong Showcases Innovative Smart PCR Lab Solution at Medica 2022

XI'AN, CHINA, Nov. 15, 2022 /PRNewswire/ -- From November 14 to 17, Tianlong's newly-launched smart PCR lab solution will showcase at Medica 2022 in Dusseldorf, Germany. The innovative smart PCR lab solution from Tianlong can maximize resources by making the best use of people, space, and equipment, and empower the PCR laboratory with high productivity and high efficiency. How can we empower PCR lab? Continue Reading Tianlong team in Medica Overview of Tianlong smart PCR lab solution Different from traditional PCR laboratories relying on manual and paper-based recording, Tianlong smart lab system can keep track of all the samples, and monitor the experiment status in real time, thus realizing rapid traceability of abnormal test results. Professionals have an unprecedented view of everything that is happening in the lab. Paperless recording removes manual, error-prone workflows. The fully automatic instrument can improve lab efficiency and standardize the process. With the innovative smart laboratory system and interconnected automatic devices, nucleic acid testing efficiency in the lab can be greatly enhanced and data integrity can be ensured. The increased connectivity and automation allow labs to work more efficiently, leading to higher-quality data with less human labor and less human error. In the smart PCR lab, human labor can decrease by 75% and testing capability can increase by 160% in an 8-hour shift when compared with a traditional PCR lab. Tianlong smart lab solution is perfect for massive testing due to its high efficiency. Up to now, Tianlong smart lab solution has been applied in many hospitals such as Beijing Children's Hospital, Beijing Tsinghua Changgeng Hospital in China mainland as well as some public health laboratory in Hong Kong, which has greatly empowered those labs with maximum efficiency. About Tianlong Tianlong is an innovative high-tech company specializing in molecular diagnostic products in China. Since its foundation in 1997, Tianlong has devoted itself to providing integrated PCR lab solutions for professionals worldwide. We have a wide range of products covering from devices to reagents, including nucleic acid extractors, Real-time PCR systems, All-in-one molecular diagnosis systems, sample processing systems, liquid handling systems, and 300 kinds of compatible reagents. With NMPA, CE, and FDA marks, our products have been exported to more than 100 countries and regions worldwide and have greatly helped the prevention and control of epidemics such as COVID-19, SARS, avian influenza, Ebola, Zika, and African swine fever. Explore Tianlong: Follow us on: LinkedIn: Facebook: Twitter: Contact us: [email protected] SOURCE Xi'an TianLong Science and Technology Co., Ltd

诊断试剂

100 项与天龙通络胶囊相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脑梗塞	临床3期	中国	牡丹江友搏药业有限责任公司	2013-07-05
颅内动脉粥样硬化	临床3期	中国	牡丹江友搏药业有限责任公司	2013-07-05
颅内栓塞	临床3期	中国	牡丹江友搏药业有限责任公司	2013-07-05
缺血性卒中	临床3期	中国	牡丹江友搏药业有限责任公司	2013-07-05
脑卒中	药物发现	中国	北京国仁堂医药科技发展有限公司	2011-03-17